11,999 Shares in Sera Prognostics, Inc. (NASDAQ:SERA) Purchased by Walleye Capital LLC

Walleye Capital LLC acquired a new position in shares of Sera Prognostics, Inc. (NASDAQ:SERA) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 11,999 shares of the company’s stock, valued at approximately $98,000.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Barclays PLC lifted its position in Sera Prognostics by 13.4% during the fourth quarter. Barclays PLC now owns 44,722 shares of the company’s stock worth $364,000 after purchasing an additional 5,272 shares during the period. Townsquare Capital LLC bought a new stake in Sera Prognostics during the fourth quarter worth about $130,000. Wells Fargo & Company MN lifted its holdings in shares of Sera Prognostics by 55.2% in the fourth quarter. Wells Fargo & Company MN now owns 13,192 shares of the company’s stock worth $107,000 after acquiring an additional 4,691 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Sera Prognostics by 2.2% in the fourth quarter. Geode Capital Management LLC now owns 599,702 shares of the company’s stock worth $4,883,000 after acquiring an additional 12,865 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Sera Prognostics by 5.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 81,228 shares of the company’s stock valued at $661,000 after purchasing an additional 4,115 shares in the last quarter. Institutional investors own 54.64% of the company’s stock.

Sera Prognostics Price Performance

SERA stock opened at $3.16 on Monday. The stock has a market cap of $119.02 million, a price-to-earnings ratio of -3.19 and a beta of 0.96. The company has a 50 day simple moving average of $3.78 and a 200 day simple moving average of $5.82. Sera Prognostics, Inc. has a 1 year low of $2.99 and a 1 year high of $12.36.

Sera Prognostics (NASDAQ:SERA) last posted its earnings results on Wednesday, March 19th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02). The business had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.01 million. During the same quarter in the previous year, the firm posted ($0.25) earnings per share. On average, equities research analysts anticipate that Sera Prognostics, Inc. will post -0.96 EPS for the current fiscal year.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.